Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Xlife Sciences AG
  6. News
  7. Summary
    XLS   CH0461929603

XLIFE SCIENCES AG

(XLS)
  Report
Delayed Swiss Exchange  -  11:30:04 2023-02-03 am EST
34.00 CHF   -2.86%
01/23Stifel initiates research coverage of Xlife Sciences
EQ
01/20Xlife Sciences Portfolio Company Receives European Patent for Biological Tissue Generation Method
MT
01/20Xlife Sciences : Swiss portfolio company Axenoll receives strategically significant patent by the European Patent OfficeTitle
EQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Xlife Sciences Begins Strategic Options Review To Accelerate Business Expansion

11/21/2022 | 01:27am EST


ę MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
SWISS LIFE HOLDING AG -0.18% 544.8 Delayed Quote.14.26%
XLIFE SCIENCES AG -2.86% 34 Delayed Quote.14.48%
All news about XLIFE SCIENCES AG
01/23Stifel initiates research coverage of Xlife Sciences
EQ
01/20Xlife Sciences Portfolio Company Receives European Patent for Biological Tissue Generat..
MT
01/20Xlife Sciences : Swiss portfolio company Axenoll receives strategically significant patent..
EQ
01/16Xlife Sciences' Portfolio Company To Research Therapy For Amyotrophic Lateral Sclerosis
MT
01/16Xlife Sciences portfolio company launches project to research a potential therapy for a..
EQ
01/16Xlife Sciences AG Launches Project to Research a Potential Therapy for Amyotrophic Late..
CI
2022Xlife Sciences Portfolio Company Signs Exclusive License Agreement
MT
2022Portfolio company Lysatpharma and joint venture Novaxomx start with research and produc..
EQ
2022Xlife Sciences Unit Taps CureDiab For Morbid Obesity Research
MT
2022Alytas therapeutics collaborates with spin-off from the German Diabetes Center
EQ
More news
Financials
Sales 2022 0,80 M 0,87 M 0,87 M
Net income 2022 -9,00 M -9,74 M -9,74 M
Net Debt 2022 62,4 M 67,6 M 67,6 M
P/E ratio 2022 -19,1x
Yield 2022 -
Capitalization 182 M 197 M 197 M
EV / Sales 2022 305x
EV / Sales 2023 307x
Nbr of Employees 13
Free-Float 45,8%
Chart XLIFE SCIENCES AG
Duration : Period :
Xlife Sciences AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends XLIFE SCIENCES AG
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 34,00 CHF
Average target price 68,00 CHF
Spread / Average Target 100%
EPS Revisions
Managers and Directors
Oliver R. Baumann Chief Executive Officer
Carl von Halem Chief Financial Officer
Bernhard Scholz Chairman-Supervisory Board
Frank Ploger Chief Scientific Officer
Christian Faber Member-Supervisory Board & Head-Legal & Compliance
Sector and Competitors
1st jan.Capi. (M$)
XLIFE SCIENCES AG14.48%197
MODERNA, INC.-1.82%66 559
LONZA GROUP AG21.92%44 368
IQVIA HOLDINGS INC.15.76%44 054
ALNYLAM PHARMACEUTICALS, INC.-3.32%28 711
SEAGEN INC.7.38%25 622